Arvinas, Inc. ARVN 深 沪
等待开盘 04-02 09:30:00 美东时间
11.33
+0.730
+6.89%
华盛通- 最 高11.35
- 今 开10.79
- 成交量 197.50万股
- 最 低 10.65
- 昨 收 10.60
- 总市值 7.25亿
- 52周最高 14.51
- 市盈率 静 --
- 换手率 3.09%
- 52周最低 5.90
- 委 比 -81.12%
- 总股本 6396.10万
- 历史最高 108.465
- 量 比 2.77
- 振 幅 6.60%
- 历史最低 5.90
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
BTIG Maintains Buy on Arvinas, Raises Price Target to $16
BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $14 to $16.
03-19 20:51
Arvinas shares are trading lower. The company presented data from a Phase 1 clinical trial of ARV-102 at AD/PD 2026.
Arvinas shares are trading lower. The company presented data from a Phase 1 cli...
03-19 00:29
Arvinas To Present Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Data For ARV-102 LRRK2 Degrader In Parkinson's Disease At AD/PD 2026
Presentation Title: Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants with Parkinson's DiseaseSession Title: Modulating Neuroinflammation, Α-Synuclein,
03-11 19:14
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Citigroup Maintains Buy on Arvinas, Raises Price Target to $18
Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $15 to $18.
03-06 02:47
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
5 Analysts Assess Arvinas: What You Need To Know
Arvinas (NASDAQ:ARVN) underwent analysis by 5 analysts in the last quarter, rev...
02-26 04:01
Wedbush Maintains Neutral on Arvinas, Raises Price Target to $11
Wedbush analyst Robert Driscoll maintains Arvinas (NASDAQ:ARVN) with a Neutral and raises the price target from $9 to $11.
02-25 21:27
Arvinas shares are trading lower after the company reported worse-than-expected Q4 financial results.
Arvinas shares are trading lower after the company reported worse-than-expected...
02-24 22:26
